20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
Ref.: C.L.30.2019
The World Health Organization (WHO) presents its compliments to Member States
and Associate Members and in reference to C.L.14.2019 has the pleasure of informing that
the 42nd Expert Committee on Drug Dependence (ECDD) will meet in Geneva from
21 to 25 October 2019. The Expert Committee on Drug Dependence meetings are of a closed
nature, however a public information session on 21 October will be open to Member States.
Further information, including a full agenda of the meeting, will be available on the ECDD
website: https://www.who.int/medicines/access/controlled-substances/ecdd/ecdd/en/.
... The 42nd ECDD will convene to review psychoactive substances (attached) regarding
their potential to cause dependence, abuse and harm to health, and their potential therapeutic
applications. WHO will make recommendations to the UN Secretary-General on the need for and
level of international control of these substances.
Member States are invited to collaborate in this process through designated national focal
points, as in the past and in line with the publication “Guidance on the WHO review of
psychoactive substances for international control” (EB126/2010/REC1, Annex 6, Para 21). 1
For this purpose, a questionnaire was designed to gather country information on the
legitimate use, harmful use, status of national control and potential impact of international
control for each substance under evaluation.
National focal points designated by Member States following C.L.14.2019 will be
approached to complete the questionnaire on substances under review at the 42nd ECDD
meeting. Focal points will be given further instructions and direct access to online
questionnaires. The questionnaires will be analysed by the Secretariat and prepared as
a report that will be shared with the Committee for review.
Focal points are also encouraged to provide any additional relevant information
(unpublished or published) on substances to be reviewed at the 42nd ECDD to:
[email protected] by 20 September 2019.
The World Health Organization takes this opportunity to renew to Member States and
Associate Members the assurance of its highest consideration.
GENEVA, 29 July 2019
1
http://apps.who.int/gb/ebwha/pdf_files/EB126-REC1/B126_REC1-en.pdf#page=95.
... ENCL.: (1)
20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT
42nd Expert Committee on Drug Dependence (ECDD)
21 to 25 October 2019, WHO headquarters, Geneva, Switzerland
Substances under review
Critical Review
Synthetic cannabinoids 1. APINACA (AKB-48)
2. AB-FUBINACA
3. 5F-AMB (5F-AMB-PINACA, 5F-MMB-PINACA)
4. 5F-MDMB-PICA (5F-MDMB-2201)
5. 4-F-MDMB-BINACA (4F-ADB)
Synthetic stimulants 6. 4-CMC (4-chloromethcathinone; clefedrone)
7. N-ethylhexedrone (NEH, Hexen, Ethyl-Hex)
8. Alpha-PHP (PV-7, α-pyrrolidinohexanophenone)
9. DOC (2,5-Dimethoxy-4-chloroamfetamine)
Fentanyl Analogues 10. Crotonylfentanyl
11. Valerylfentanyl
Benzodiazepines 12. Flualprazolam
13. Etizolam
Pre-review
Preparations listed in Preparations of:
Schedule III of the 1961
Single Convention on o Acetyldihydrocodeine
Narcotic Drugs o Codeine
o Dihydrocodeine
o Ethylmorphine
o Nicocodine
o Nicodicodine
o Norcodeine
o Pholcodine
when compounded with one or more other ingredients and
containing not more than 100 milligrams of the drug per
dosage unit and with a concentration of not more than
2.5 per cent in undivided preparations.